The expression and location of sodium / iodide symporter (NIS) in differentiated thyroid carcinoma and corresponding lymph nodes metastasis

Transcript

1 1082 ( ) ACTA UNIVERSITATIS MEDICINALIS NANJING(Natural Science) / ( ) [ ] : / (sodium / iodide symporternis) : (real time polymerase chain reactionrt-pcr) NIS :RT-PCR : NIS mrna NIS mrna :NIS NIS NIS : NIS NIS [ ] / ; ; [ ] R736.1 [ ] A [ ] (10) The expression and location of sodium / iodide symporter (NIS) in differentiated thyroid carcinoma and corresponding lymph nodes metastasis HU Yang-yingSHEN Mei-ping (Department of General Surgerythe First Affiliated Hospital of NJMUNanjing China) [Abstract] Objective:To study the gene expression of sodium / iodide symporter (NIS) in both differentiated thyroid carcinoma (DTC)and correlated lymph nodes metastasisand explore the relationship between NIS expression and DTCand between NIS expression and the significance of radioactive iodine treatment for DTC. Methods:The expression of NIS in tissue specimens was evaluated by RT-PCR technique and immunohistochemistry. Results:The RT-PCR result showed that the expression of NIS mrna didn t have significant difference between tumor-adjacent tissues and DTC tissues. The NIS mrna expression in metastatic lymph nodes were lower compared with tumor and tumor-adjacent tissues. The immunohistochemistry result showed that NIS positive ratio in DTC and correlated lymph nodes tissue didn t have significant difference compared with that in normal thyroidrespectively. Conclusion:The NIS could be normally expressedbut NIS protein was mostly expressed in the cytoplasm rather than in the functional membranewhich has guiding significance for the radioiodine treatment of DTC. [Key words] sodium / iodide symporter; differentiated thyroid carcinoma; lymph nodes metastasis [Acta Univ Med Nanjing 10 30(08): ] / (sodium / iodide symporternis) 643 NIS [1] NIS NIS (Western blot ) NIS [ ] (BZ09053) NIS nj-shenmp@sina.com [2]

2 30 8 (real time PCR polymerase chain reactionrt-pcr) NIS RCR : :5 -GTCGTG- NIS GTGATGCTAAGTG-3 :5 -CTCGGG- NIS TCAGGGTTAAAG bp β-actin :5 -TTGCGTTACAC- CCTTTCTT-3 :5 -TGTCACCTTCAC- 1 CGTTCC-3 :150 bp PCR 1.1 NIS PCR 3 RT-RCR : ~09 4 I TSH 48 4% 38 HE HE (graves ) 10 [3-4] : 4 μm 50 SP ~71 < NCCN TNM PBS TRIzol RT ( Promega )PCR ( )SYBR 2 Green ( Takara ) PCR 7500( ABI )NIS 2.1 RT-PCR NIS ( MILLIPORE ) RT-PCR : / RNA TRIzol ( ± ) (P > RNA RNA 0.05); CT ± 1% RNA RNA CT (P < cdna PCR 1) RT-PCR CT CT ( Ct=Ct -Ct ) 2 - Ct ( Ct= Ct - Ct ) SPSS 13.0 Tamhane s T2 Fisher P < 0.05 Ct ± (P < 0.05);

3 NIS % ; NIS % ; NIS 28 57% Ct NIS 1 NIS (P < ) P < 0.05; # P < 1 PCR NIS NIS Fig 1 The RT-PCR result of the expression of NIS in thyroid (P > 0.053) tissues of different groups # Ct 2 - Ct 1 RT-PCR NIS mrna Tab 1 The RT-PCR result of the mrna expression of NIS in thyroid tissues of different groups (x ± s) (n=38) ± ± P < 0.05; # P < (n=24) (n=15) (n=10) ± ± ± ± # ± # A B C A: NIS (400 ); B: NIS (400 ); C: NIS (0 ) Fig 2 2 NIS The expression of NIS in each thyroid tissue by immunohistochemistry technique 2 NIS + + I I Tab 2 The expression of NIS in DTC by immunohistochemistry technique in different groups (n/n) I ( / ) ( / ) [5-6] 33 / 16 1 / / 21 8 / 41 [7] NIS 34 / 15 1 / 48 P < 0.05 NIS 3 NIS NIS

4 30 8 : / Tab 3 3 NIS TMN The expression of NIS in patients with different agesgenders and TNM staging by immunohistochemistry technique (n = 15) (n = 34) < 45 (n = 29) (n = ) ~ (n = 30) TMN (n) ~ (n = 19) [18-9] NIS 3.3 NIS Ringel [10] NIS Dohán [11] NIS NIS RT- NIS PCR NIS NIS 3.1 NIS NIS RT-PCR NIS mrna NIS NIS NIS NIS NIS 49 NIS 1 [13-15] (P < 0.05) NIS NIS NIS [12] ECT (Western blot) [ ] NIS [1] Dohán ODe la Vieja AParoder Vet al. The sodium / iodide symporter(nis):characterizationregulationand med- [2] ical significance[j]. Endocr Rev0324(1): NIS [2]. / RT-PCR [J]. ( )0828(8): NIS mrna [3]. (P < 0.05) [J] : NIS % [4] Kononen JBubendorf LKallioniemi Aet al. Tissue mi- for high-throughput molecular profiling of tumor NIS croarrays NIS specimens[j]. Nat Med19984(7): ( 1216 )

5 [ ] (06 )[J] (9): [2]. [M]. : 1994:-132 [3] Melzack R. The McGill Pain Questionnaire:major properties and scoring methods[j]. Pain19751(3):277 :1 [4] Jorge JMNWexner SD. Etiology and management of fecal incontinence [J]. Dis Colon Rectum (1): ;2 8 ; [5]. [M]. : 1985:631 ;4 [6] Milligan ETCMorgan CNNanton LEet al. Surgical ;5 anatomy of the anal canal and the operative treatment of hemorrhoids[j]. Lancet19372:1119 [7] Thomson WH. The nature of hemorrhoids [J]. Br J Surg : [8] Gould RP. Sensory innervation of the anal canal[j]. Na- ture :337 [9]. [J]. 0915(5): [1]. [ ] !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! ( 1085 ) [5] Quiros RMDing HGGattuso Pet al. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations[j]. Cancer05103(11):2261 [6] Wang HFu HLLi JNet al. Comparis on of whole - body 18F-FDG SPECT and posttherapeutic I scintigraphy in the detection of meta-static thyroid cancer [J]. Clin Imaging0832(1):32 [7]. [13] Kogai TTaki KBrent GA. Enhancement of sodium / iodide symporter expression in thyroid and breast cancer I [J]. 0922(2): [8] Saito TEndo TKawaguchi Aet al. Increased expression of the sodium / iodide symporter in papillary thyroid carcinomas[j]. Clin Invest (7): (4): [11] Dohán OBaloch ZBánrévi Zet al. Rapid communication:predominant intracellular overexpression of the Na (+) / I (-)symporter (NIS)in a large sampling of thyroid cancer cases [J]. Clin Endocrinol Metab0186 (6): [12] Brave man LEUtiger RD. Werner and Ingbar s the thyroid:a fundamental and clinical text[m]. 8th ed. Philadelphia:Lippincott-Williams & Wilkins00: [J]. Endocr Relat Cancer0613(3): [14]. [J]. 0810: [9]. / [15] Wapnir ILvan de Rijn MNowels Ket al. Immunohistochemical [J]. ( )0222(4): [10] Ringel MDAnderson JSouza SLet al. Expression of the sodium iodide symporter and thyroglobulin genes are reduced profile of the sodium / iodide symporter in thy- roidbreastand other carcinomas using high density tissue microarrays and conventional sections [J]. Clin Endocrinol Metab0388(4): in papillary thyroid cancer [J]. Mod Pathol [ ]